ZKSCAN3 and plasma cell myeloma: Potential involvement of ZKSCAN3 was reported in colorectal cancer (Cho et al., 2022; Kim et al., 2016; Yang et al., 2008a; Yang et al., 2008b), liver cancer (Li et al., 2020), multiple myeloma (Yang et al., 2011), prostate cancer (Zhang et al., 2012), bladder cancer (Kawahara et al., 2016), breast cancer (Chi et al., 2018), cervical cancer (Lee et al., 2018), and gastric cancer (Takano et al., 2020).